CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Feasibility and benefits of systemic second-line therapy in advanced hepatocellular carcinoma (HCC) – a retrospective analysis
DOI 10.1055/s-0033-1360896
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Koch, A Weinmann, JU Marquardt, PR Galle, MA Wörns
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Sorafenib is the systemic first-line therapy (ST1) standard in patients (pts) with advanced hepatocellular carcinoma (HCC). The feasibility and benefits of systemic second-line therapy (ST2) are unclear. Methods: Retrospective analysis of pts with advanced HCC treated with sorafenib from January 2007 to June 2012 at the University Medical Center of the Johannes Gutenberg University Mainz, Germany. Pts…
Zitieren
Zitierempfehlung
S Koch, A Weinmann, JU Marquardt, PR Galle, MA Wörns (2014) Feasibility and benefits of systemic second-line therapy in advanced hepatocellular carcinoma (HCC) – a retrospective analysis. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0033-1360896
Mit CareLit weiterarbeiten